Hubei Biocause Heilen Pharmaceutical (301211.SZ): Ibuprofen sustained-release capsules obtain drug registration certificate.
Hengdian Pharmaceutical (301211.SZ) announced that the company recently received a notice from the National Medical Products Administration (NMPA)...
Hubei Biocause Heilen Pharmaceutical (301211.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration, involving the product: "Ibuprofen Sustained-Release Capsules".
The company's Ibuprofen Sustained-Release Capsules have obtained the drug registration certificate from the National Medical Products Administration, indicating that the company has the qualification to sell this drug in the domestic market. This further enriches the company's product line and signifies a new breakthrough in the company's "raw material drug formulation integration" strategy.
Related Articles
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
